|
|
Article: Targeted Genetics and Biogen Announce Product Development and Commercialization Collaboration Valued At Up to $125 Million.
- Article from:
- Business Wire
- Article date:
- August 9, 2000
CopyrightCOPYRIGHT 2000 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Medical Writers
SEATTLE--(BW HealthWire)--Aug. 9, 2000
Targeted Genetics Corporation (Nasdaq:TGEN) today announced that the company has entered into a definitive agreement to establish a major multi-product development and commercialization collaboration with Biogen, Inc.
The collaboration replaces and expands an agreement that Biogen established in 1995 with Genovo, a privately-held gene therapy company to be acquired by Targeted Genetics (see accompanying press release), and in which Biogen is a significant shareholder.
Under the terms of the agreement, Targeted Genetics will work on the development of up to ...